M.D. Anderson Cancer Center
This clinical research study is to learn if CD70.CAR NK cell therapy can help to control early relapsed or primary refractory DLBCL and cHL.
Primary Objective: The primary objective of the study is to determine the efficacy of CB-derived CD70.CAR NK cell therapy in patients with primary refractory or early relapsed DLBCL and HL, as determined by the 2-year event-free survival rate. Secondary Objectives: * To determine the antitumor activity pf CB-derived CD70.CAR NK cells, as determined by the response rate (ORR) and complete response (CR) rate. * To establish the safety of this treatment. * To quantify the persistence of infused CB-derived CD70.CAR NK cells in the peripheral blood. * To conduct comprehensive immune studies by e…
Inclusion Criteria: 1. 18-75 years of age. 2. Diagnosis of cHL or DLBCL that is either: * Primary refractory, defined as not having achieved a CR with frontline therapy or having relapsed within 3 months. * Early relapsed (≤ 12 months) after achieving a CR to frontline therapy. 3. Tumor biopsy positive for CD70 \>/= 10% by immunohistochemistry or flow cytometry. 4. Measurable disease, defined by one or more histologically confirmed hypermetabolic lesion on PET/CT scan. 5. ECOG PS ≤ 2 (Karnofsky ≥60%). 6. Adequate blood counts (WBC \> 2K, HGB \> 8 g/dL, platelets \> 50K). 7. Creatinine…
Given by IV
Given by IV
Given by IV Infusion
Given by IV Infusion
Arctuva estimate
Verify or correct the compensation shown for this listing.